Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 779-790

  Augustine, Christina ^a,c,d   Jung, Sin Ho ^a   Sohn, Insuk ^a   Yoo, Jin Soo ^a   Yoshimoto, Yasunori ^e   Olson Jr , John A ^a,b   Friedman, Henry S ^a   Ali Osman, Francis ^c   Tyler, Douglas S ^a,d  

^a Department of Surgery ^*  (Japan)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Durham Veteran's Affairs Medical Center   (Canada)

^e YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MELPHALAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; NERVE CELL ADHESION MOLECULE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; IN-TRANSIT METASTASIS; MALE; MELANOMA; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 77950827393     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0764     Document Type: Article

References (43)

1. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel Iymphadenectomy. Ann Surg Oncol 2005;12:587-596
2. Kretschmer L, Beckmann I, Thorns KM, Mitteldorf C, Bertsch HP, Neumann C. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann Surg Oncol 2006;13:1105-1112
3. Bild A, Febbo PG. Application of a priori established gene sets to discover biologically important differential expression in microarray data. Proc Natl Acad Sci U S A 2005;102:15278-15279
4. John T, Black MA, Toro TT, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008;14: 5173-5180
5. Winnepenninckx V, Lazar V, Michlels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-482
6. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001;117:1483-1489
7. Wiltshire RN, Duray P, Bittner ML, et al. Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res 1995;55:3954-3957
8. Wang E, Volculescu S, Le Poole IC, et al. Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol 2006;126:1372-1377
9. Nakayama T, Taback B, Turner R, Morton DL, Hoon DS. Molecular clonality of in-transit melanoma metastasis. Am J Pathol 2001;158: 1371-1378
10. Sabatino M, Zhao Y, Voiculescu S, et al. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 2008;68:122-131
11. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005;102:6092-6097
12. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F. A Model Based Background Adjustment for Oligonucleotide Expression Arrays. Working papers. Baltimore, MD: John Hopkins University, Dept. of Biostatistics; 2004.
13. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistlcs 2003;4:249-264
14. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193
15. Donner A. A review of inference procedures for the intraclass correlation coefficient in the one-way random effects model. International Statistical Review 1986;54:67-82.
16. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868
17. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Blometrika 1986;73:13-22.
18. Augustine CK, Yoo JS, Potti A, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009;15:502-510
19. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357
20. Dressman HK, Berchuck A, Chan G, et al. An integrated genomicbased approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525
21. Pavey S, Johansson P, Packer L, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-4067
22. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 2007;20:216-221
23. Bloethner S, Chen B, Hemminki K, et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 2005;26:1224-1232
24. Dhomen N, Marais R. New insight Into BRAF mutations in cancer. Curr Opin Genet Dev 2007;17:31-39
25. Hoek KS, Schlegel NC, Brafford P, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19:290-302.
26. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-586
27. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64:2338-2342
28. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-5202
29. Stelngrlmsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 2004;38:365-411.
30. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses Identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-122
31. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12:406-414
32. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005;168:35-40.
33. Ugurel S, Houben R, Schrama D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007;13:6344-6350
34. Cronin JC, Wunderlich J, Loftus SK, et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 2009;22: 435-444
35. Duncan LM, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998;58:1515-1520
36. Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 2004; 64:509-516
37. Wellbrock C, Marais R. Elevated expression of MITF counteracts BRAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005;170:703-708
38. Gupta V, Jani JP, Jacobs S, et al. Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. Cancer Chemother Pharmacol 1995;36:13-19
39. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55:2853-2857
40. Grubbs EG, Ueno T, Abdel-Wahab O, et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004;136:210-218
41. Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomlde as regional chemotherapeutic agents. Mol Cancer Ther 2007;6:1492-1500
42. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356: 1728-1733
43. Stein U, Jurchott K, Schlafke M, Hohenberger P. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic Isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 2002;20:3282-3292